Literature DB >> 9121988

Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease?

C Muratore1, R Rabinovich, R Iglesias, M González, V Darú, A S Liprandi.   

Abstract

Chagas' disease is a parasitic affliction, endemic to certain regions of South America, which may lead to a chronic dilated nonischemic cardiomyopathy. Ten Chagasic patients were compared to 18 coronary patients undergoing transvenous ICD implantation for ventricular tachycardia (VT), ventricular fibrillation (VF), or aborted cardiac arrest. Indications for ICD implantation were either drug intolerance or refractoriness, or no inducible tachyarrhythmia at EPS. There were no statistically significant differences between the Chagas and coronary artery disease groups with respect to age (60.2 vs 62.6 yrs), NYHA Class II (50% vs 62%), ejection fraction (31.1% vs 29.7%), and incidence of cardiac arrest (20% vs 33%), respectively. The following ICD implant and long-term follow-up variables were compared between the two groups: pacing threshold (0.94 V vs 0.95 V), defibrillation threshold (19.5 J vs 19.6 J), number of VT episodes (414 vs 435), number of spontaneous VT terminations (86 vs 187), percent efficacy of antitachycardia pacing (93.9% vs 92.1%), and total number of shocks (112 vs 145). These differences were not statistically significant. We conclude that patients with Chagas' disease, compared with coronary artery disease patients, have similar clinical characteristics leading to ICD implantation. Furthermore, no differences were found with respect to ICD and long-term follow-up characteristics between the two groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121988     DOI: 10.1111/j.1540-8159.1997.tb04841.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

Review 1.  Our search for the porcine mother rotor.

Authors:  Raymond E Ideker; Jian Huang
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

Review 2.  Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy.

Authors:  Claudio A Muratore; Adrian Baranchuk
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

3.  Clinical Course After Cardioverter-Defibrillator Implantation: Chagasic Versus Ischemic Patients.

Authors:  Francisca Tatiana Moreira Pereira; Eduardo Arrais Rocha; Marcelo de Paula Martins Monteiro; Neiberg de Alcantara Lima; Carlos Roberto Martins Rodrigues Sobrinho; Roberto da Justa Pires Neto
Journal:  Arq Bras Cardiol       Date:  2016-07-11       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.